Promising clinical data from Kiadis Pharma’s lead product ATIR presented by NIH investigators
Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained so far in a physician initiated clinical study for ATIR™. At the EBMT meeting in Florence Dr. Mielke will present results of the ongoing phase II clinical trial of ATIR™ in matched allogeneic transplantations that is running at the NIH under an FDA approved IND.
